Vir Biotechnology, Inc.
Financials
Valuation Metrics
Vir Biotechnology, Inc.'s Market Cap is $1.50B. At end of 2025 it was $840M. Ranked #2247 of 3,112 in US market (top 72%), #894 of 1,445 on NASDAQ (top 62%), #166 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.50B | US#2,247/3,112 Sec#166/269 |
| Revenue | $65M | US#2,841/3,112 Sec#147/269 |
| Net Income | $-443M | US—/3,112 Sec—/269 |
| Total Assets | $1.03B | US#2,436/3,112 Sec#98/269 |
| Net Assets | $813M | US#1,913/3,112 Sec#73/269 |
| Employees | 367 | US#1,387/3,112 Sec#51/269 |
| Value | ||
| P/B | 1.85x | US#1,096/3,112 Sec#49/269 |
| P/S | 22.92x | US#2,833/3,112 Sec#152/269 |
| FCF Yield | -29.63% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -54.47% | US#2,756/3,112 Sec#180/269 |
| ROA | -43.17% | US#2,937/3,112 Sec#198/269 |
| Op. Margin | -704.87% | US#2,910/3,112 Sec#172/269 |
| Revenue Growth | -100.96% | US#2,970/3,112 Sec#206/269 |
| Financial Health | ||
| Debt Ratio | 26.18% | US#285/3,112 Sec#94/269 |
| Total Debt | $96M | US#2,400/3,112 Sec#120/269 |
| FCF | $-445M | US#2,826/3,112 Sec#256/269 |
| Cash | $276M | US#1,484/3,112 Sec#89/269 |
| Current Ratio | 7.11x | US#334/3,112 Sec#108/269 |
| Performance | ||
| 1Y Return | 76.94% | US#454/3,112 Sec#98/269 |
| 1M Return | -11.35% | US#2,671/3,112 Sec#180/269 |
| From 52W High | -23.67% | US#1,891/3,112 Sec#130/269 |
| 1Y MDD | -27.82% | US#1,226/3,112 Sec#75/269 |
| Trading | ||
| Volume | 1,220,053 shares | US#1,320/3,112 Sec#133/269 |
| Trading Value | $11M | US#2,301/3,112 Sec#183/269 |
| Per Share | ||
| EPS | $-3.15 | US—/3,112 Sec—/269 |
| BPS | $5.50 | US#2,181/3,112 Sec#125/269 |
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.